Oncology Xagena
Telomerase reverse transcriptase ( hTERT ) represents an attractive target for cancer immunotherapy because hTERT is reactivated in most human tumors. A Phase 1-2 clinical trial evaluated telomeras ...
Important new data on MPDL3280A ( RG7446, also known as anti-PDL1 ) were presented at the 2013 European Cancer Congress ( ECC ).The data from an updated analysis of a Phase 1 study assessing MPDL3280A ...
Merck Serono has announced the decision to continue clinical development of its investigational MUC1 antigen-specific cancer immunotherapy Tecemotide under a new phase III trial called START2 for pati ...
Lancet Oncology has published results from the phase III trial of its investigational MUC1 antigen specific cancer immunotherapy Tecemotide ( also known as L-BLP25 ) in patients with unresectable, loc ...
A review, titled Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential, from researchers at The University of Texas MD Anderson Cancer Center published i ...
Early results from a pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with locally advanced or metastatic urothelial car ...
Positive results from two phase II studies that evaluated the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with advanced non-small cell lung cancer ( NSCLC ) we ...
In the large pivotal phase II study, BIRCH, the investigational cancer immunotherapy Atezolizumab ( MPDL3280A; anti-PD-L1 ) met its primary endpoint and shrank tumors ( objective response rate; ORR ) ...
Updated results from the pivotal phase II study, IMvigor 210, of the investigational cancer immunotherapy Atezolizumab ( MPDL3280A ) in people with locally advanced or metastatic urothelial carcinoma ...
Researchers at the University of Texas MD Anderson Cancer Center in Houston, have found a link between microbes in the gut ( the microbiome ) and response to immunotherapy. In the study, the ability o ...
The immunomodulatory receptor TIGIT is a novel inhibitory immune checkpoint present on activated T cells and NK cells in multiple cancers, including non-small-cell lung cancer ( NSCLC ). In a phas ...
